Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.
Smit
Egbert F
EF
Department of Pulmonary Diseases, Vrije Unversiteit Medical Centre, Amsterdam, The Netherlands. ef.smit@vumc.nl
Dingemans
Anne-Marie C
AM
Thunnissen
Frederik B
FB
Hochstenbach
Monique M
MM
van Suylen
Robert-Jan
RJ
Postmus
Pieter E
PE
D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D018287:Carcinoma, Large Cell / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D011725:Pyridines / Q000627:therapeutic use*; D000077157:Sorafenib; D015996:Survival Rate; D016896:Treatment Outcome; D018631:ras Proteins / Q000235:genetics*
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; C117307:KRAS protein, human; D010671:Phenylurea Compounds; D011518:Proto-Oncogene Proteins; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins